How to find us

Event location
Bayerische Landesärztekammer (BLÄK)/
State Chamber of Physicians of Bavaria
Mühlbaurstraße 16
81677 Munich, Germany

Registration
Please register to participate by 17 April 2024 at:
www.leopoldina.org/registration-vulnerable-people/

The Leopoldina originated in 1652 as a classical scholarly society and now has 1,600 members from almost all branches of science. In 2008, the Leopoldina was appointed as the German National Academy of Sciences and, in this capacity, was invested with two major objectives: representing the German scientific community internationally, and providing policymakers and the public with science-based advice.

The Leopoldina champions the freedom and appreciation of science. It promotes a scientifically enlightened society and the responsible application of scientific insight for the benefit of humankind and the natural world. In its interdisciplinary discourse, the Academy transcends thematic, political and cultural boundaries. It is also an advocate of human rights.

Research with vulnerable people

A targeted interdisciplinary discussion within the scope of the WMA Declaration of Helsinki revision

Contact
German National Academy of Sciences Leopoldina
Dr. Stefanie Bohley, E-Mail: stefanie.bohley@leopoldina.org
German Medical Association
Dr. Ramin Parsa-Parsi, E-Mail: international@baek.de

14 – 15 May 2024
State Chamber of Physicians of Bavaria (BLÄK)
Mühlbaurstraße 16
81677 Munich, Germany

In collaboration with

With kind support of

[Logos and images]
Research with vulnerable people

A targeted interdisciplinary discussion within the scope of the WMA Declaration of Helsinki revision

In July 2023, the German National Academy of Sciences Leopoldina established a working group focused on the Framework Conditions for Clinical Trials on Vulnerable People. The objective of the working group is to demonstrate ethically justified improvements to the framework conditions for clinical studies on vulnerable people, particularly children and adolescents.

Co-organised by the Leopoldina and the German Medical Association, in collaboration with the World Medical Association and the American Medical Association, and with kind support from the State Chamber of Physicians of Bavaria, the conference "Research with vulnerable people" represents one aspect of the working group’s approach. This targeted interdisciplinary discussion will be held within the scope of the ongoing revision of the World Medical Association’s Declaration of Helsinki (DoH). The aim of this meeting is to foster discussion on the paragraphs in the DoH focused on vulnerability with proven experts and then to proactively contribute the resulting findings to the revision process.

Day 1 – 14 May 2024

12:00 – 01:00 pm | Lunch for all participants
Chair: Jung-Yul Park, MD, Chair of Council, World Medical Association

02:00 – 02:30 pm
Welcome remarks
Gerald Quitterer, MD, President, Bavarian State Chamber of Physicians
Lujain AlQodmani, MD, WMA President
Gerald Haug, PhD, President, Leopoldina
Klaus Reinhardt, MD, President, German Medical Association

02:30 – 02:45 pm
Brief introduction and history of the WMA Declaration of Helsinki
Ramin Parsa-Parsi, MD, MPH, Head of Department for International Affairs, German Medical Association

02:45 – 03:00 pm
Introduction to the current DoH revision process and recap of previous WMA conferences on vulnerable groups
Jack Resneck, MD, Chair of WMA DoH Workgroup, AMA immediate past president

03:00 – 03:15 pm
Introduction to the current discussion in the Leopoldina workgroup
Urban Wiesing ML, MD, PhD, Chair of Leopoldina WG on vulnerable people

03:15 – 03:30 pm
Mapping of vulnerability
Pierre Mermet-Bouvier, Senior Manager, eCOA, ICON, France

03:30 – 04:00 pm | Coffee break

04:00 – 05:00 pm
Analysis of vulnerability
Samia Hurst, Director, Institute for Ethics, History, and the Humanities, University of Geneva, Switzerland

Vulnerability in different research settings
Florencia Luna, Principal Researcher, FLACSO / CONICET, Argentina

Vulnerability as defined in the CIOMS guidelines
Rieke van der Graaf, Julius Center, Department of Global Public Health & Bioethics, UMC Utrecht, Netherlands

Regulatory Perspectives on Research in Vulnerable Populations
Hilary Marston, Chief Medical Officer Food & Drug Administration (FDA), US

05:00 – 05:45 pm
Panel discussion
Panel: Drs. Mermet, Hurst, Luna, van der Graaf, Marston
Moderator: Steinnunn Börðardóttir, MD, Chair, WMA Medical Ethics Committee

06:00 pm | Dinner

End of meeting

Day 2 – 15 May 2024

Chair: Stefan Pfister ML, MD, Chair of Leopoldina WG on vulnerable people

02:00 – 02:45 pm
Regulatory perspectives on age-inclusive research
Steffen Thirstrup, MD, PhD, Chief Medical Officer, European Medicines Agency

Children, subsidiarity of research
Olaf Witt, Hopp Children’s Cancer Center (KITZ), DKFZ and University Hospital Heidelberg, Germany

Conditions under which research with vulnerable groups should be permitted
Alex John London, Director, Center for Ethics and Policy, Carnegie Mellon University, US

Conducting research with Vulnerable Populations: Challenges and opportunities
Adam C. Berger, Director, Division of Clinical and Healthcare Research Policy, National Institutes of Health (NIH), US

Ethical considerations in clinical research with people with disabilities
Mohammed Ghaly, Professor of Islam and Biomedical Ethics at the Research Center for Islamic Legislation & Ethics (CILE) at the College of Islamic Studies, Qatar

10:30 – 11:00 am | Coffee break

11:00 am – 12:30 pm
Panel discussion and review of the WMA DoH paragraph on vulnerable groups
Hussain Jafri, PhD, World Patients Alliance
Moderator: Jack Resneck, MD, Chair of WMA DoH workgroup

12:30 – 01:30 pm | Lunch for all participants

End of meeting

ML – Member of the Leopoldina